10 citations
,
September 2021 in “JAMA Dermatology” This study reports that persistent chemotherapy-induced alopecia in breast cancer patients frequently resembles androgenetic alopecia, and treatment with minoxidil, alone or with antiandrogens, improved hair density in many cases.
86 citations
,
November 2020 in “Annals of Oncology” These guidelines discuss prevention and management strategies for dermatological toxicities but report no new clinical results; they include expert recommendations for conditions like acneiform rash and hand-foot syndrome.
19 citations
,
July 2020 in “Journal of cancer survivorship” This review discusses the unmet supportive care needs of men and women experiencing chemotherapy-induced alopecia and reports no new results, urging healthcare providers to tailor interventions to individual patient needs.
59 citations
,
August 2018 in “The oncologist” This study found that permanent chemotherapy-induced alopecia was relatively common three years after treatment among breast cancer patients receiving adjuvant chemotherapy, particularly those on taxane-based regimens.
23 citations
,
July 2018 in “Journal of Cosmetic Dermatology” This study describes a distinct pattern of trichoscopic features associated with chemotherapy-induced alopecia and how these features evolve through different phases of chemotherapy treatment.
53 citations
,
April 2018 in “Journal of The American Academy of Dermatology” This article reviews therapy-related hair disorders in oncology patients, detailing underlying mechanisms and potential management strategies, but reports no new clinical findings.
67 citations
,
April 2018 in “JAMA Dermatology” This study found that endocrine therapy for breast cancer is associated with a pattern of hair loss similar to androgenetic alopecia, negatively impacting quality of life despite mild severity.
37 citations
,
October 2017 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This literature review reported that scalp hypothermia significantly decreases the occurrence of chemotherapy-induced alopecia, increasing effectiveness by 2.7-fold in controlled clinical trials and 3.9-fold in randomized trials, and highlighted a need for standard guidelines for its use.
38 citations
,
September 2017 in “Oncologist” This source reports that scalp cooling is currently the only safe and FDA-cleared method to potentially reduce chemotherapy-induced hair loss, with about a 50% chance of maintaining sufficient hair to avoid needing a wig.
22 citations
,
May 2016 in “Breast cancer research and treatment” This study reported cold thermal injuries on the scalp in four patients using cold caps to prevent chemotherapy-induced alopecia, suggesting improper application can lead to adverse events.
15 citations
,
January 2015 in “Skin Pharmacology and Physiology” This study indicates that targeting the PTH/PTHrP receptor may potentially stimulate hair growth, particularly for chemotherapy-induced alopecia, as observed in hairless and cyclophosphamide-treated mice.
110 citations
,
August 2014 in “International journal of cancer” This study found that scalp cooling significantly reduced the risk of chemotherapy-induced alopecia in breast cancer patients, while topical minoxidil and other interventions did not show significant efficacy.
34 citations
,
November 2013 in “Breast Cancer Research and Treatment” This study found that female breast cancer survivors using aromatase inhibitors were observed to have a higher likelihood of experiencing hair loss and thinning compared to those not treated with these drugs.
24 citations
,
November 2013 in “British Journal of Dermatology” This study found that chemotherapy in female breast cancer patients caused significant early hair loss, which began to recover three months after completion, whereas tamoxifen did not affect hair growth.
20 citations
,
September 2013 in “Anti-Cancer Drugs” In this study, PTH-CBD effectively prevented and partially reversed chemotherapy-induced alopecia in mice, with pretreatment offering a better cosmetic outcome compared to therapeutic administration after hair loss onset.
218 citations
,
January 2013 in “The Lancet Oncology” This review discusses the pathobiology of chemotherapy-induced alopecia and highlights challenges in managing it, reporting no new clinical results and emphasizing the need for well-designed preclinical models to develop effective treatments.
14 citations
,
January 2013 in “Journal of Cutaneous Medicine and Surgery” This study describes permanent scalp alopecia in patients receiving chemotherapy, radiation, or both, and highlights the need for further research to identify causative factors and mitigation strategies.
103 citations
,
December 2011 in “Journal of the American Academy of Dermatology” This review discusses current knowledge and management strategies for chemotherapy-induced alopecia, highlighting the need for better research prioritization and providing patient support materials, but reports no new clinical results.
44 citations
,
November 2010 in “Current Opinion in Supportive and Palliative Care” This review discusses interventions for chemotherapy-induced hair loss and reports no new clinical results; scalp cooling and nutritional support are considered potential strategies but not yet substantiated.
52 citations
,
May 1993 in “Southern Medical Journal” This study found that Imuvert consistently protected against alopecia induced by certain chemotherapy drugs in rats, potentially mediated by a monocyte-derived cytokine like interleukin-1.
